2012 patent expiries will undermine pharma industry
This article was originally published in Scrip
Executive Summary
While the marquee event for the pharma industry in 2011 was the long awaited expiry of the US patent protecting Lipitor (atorvastatin), an additional $30 billion in US sales of other blockbuster drugs are at risk in 2012.